Core Viewpoint - Company will showcase its pipeline asset CS2015 at the upcoming ACAAI annual scientific meeting in 2025, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulators that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, thereby extending its half-life in circulation and optimizing pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations and ensuring scalability for production [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website, enhancing visibility within the scientific community [1]
ACAAI 2025|基石药业-B(02616.HK)CS2015(OX40L/TSLP双特异性抗体)首次亮相国际学术舞台